Encyclopedia of Experiments: Immunology
A subscription to JoVE is required to view this content. Sign in or start your free trial.
Transcript
Begin with serially diluted human serum containing varying concentrations of neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 or SARS-CoV-2.
Introduce pseudotyped viruses with luciferase RNA, integrase, and reverse transcriptase, encapsulated within a lipid bilayer containing SARS-CoV-2 spike proteins.
Antibodies neutralize the viruses based on serum dilution, with lower dilutions exhibiting maximum neutralization.
Introduce target cells expressing angiotensin-converting enzyme-2 receptors or ACE2 receptors and transmembrane protease serine-2 or TMPRSS2.
In higher serum dilutions, non-neutralized viruses interact with ACE2 receptors, while TMPRSS2 cleaves the spike protein, enabling virus fusion.
Upon entry, luciferase RNA is reverse-transcribed to DNA that integrates into the host genome and produces luciferase enzyme.
Replace the medium with an assay buffer containing luciferase substrate and a lysing agent.
The cells lyse, releasing intracellular luciferase, which interacts with the substrate and produces high luminescence.
Quantify luminescence across serum dilutions to determine viral neutralization percentage — the dilution achieving fifty percent neutralization represents the neutralization titer.